tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Keros Therapeutics Concludes Strategic Alternatives Review
PremiumCompany AnnouncementsKeros Therapeutics Concludes Strategic Alternatives Review
1M ago
Keros Therapeutics to return $375M in excess capital to stockholders
Premium
The Fly
Keros Therapeutics to return $375M in excess capital to stockholders
1M ago
Keros Therapeutics CEO to Speak at Healthcare Conference
Premium
Company Announcements
Keros Therapeutics CEO to Speak at Healthcare Conference
1M ago
Keros Therapeutics reducing headcount by 45%
PremiumThe FlyKeros Therapeutics reducing headcount by 45%
2M ago
Keros Therapeutics price target lowered to $32 from $33 at BofA
Premium
The Fly
Keros Therapeutics price target lowered to $32 from $33 at BofA
2M ago
ADAR1 announces advisor recommendation to Keros stockholders to withhold votes
Premium
The Fly
ADAR1 announces advisor recommendation to Keros stockholders to withhold votes
2M ago
Keros Therapeutics price target lowered to $25 from $40 at H.C. Wainwright
PremiumThe FlyKeros Therapeutics price target lowered to $25 from $40 at H.C. Wainwright
2M ago
Keros Therapeutics: Buy Rating Affirmed Amid Promising Trial Data and Strategic Initiatives
Premium
Ratings
Keros Therapeutics: Buy Rating Affirmed Amid Promising Trial Data and Strategic Initiatives
2M ago
Keros Therapeutics Reports Strong Q1 2025 Results
Premium
Company Announcements
Keros Therapeutics Reports Strong Q1 2025 Results
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100